Cardioprotective effects of tanshinone IIA pretreatment via kinin B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic cardiomyopathy

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Sun, Dongdong ^a   Shen, Min ^a   Li, Jiayi ^a   Li, Weijie ^a   Zhang, Yingmei ^a   Zhao, Li ^a   Zhang, Zheng ^a   Yuan, Yuan ^a   Wang, Haichang ^a   Cao, Feng ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRADYKININ B2 RECEPTOR; GLYCOGEN SYNTHASE KINASE 3BETA; ICATIBANT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MYELOPEROXIDASE; PROTEIN KINASE B; STREPTOZOCIN; TANSHINONE IIA; TUMOR NECROSIS FACTOR; ABIETANE DERIVATIVE; BRADYKININ; CARDIOTONIC AGENT; DRUG DERIVATIVE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; PEROXIDASE; TANSHINONE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DRUG EFFECT; ENZYME ACTIVITY; HEART CONTRACTION; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; HEART MUSCLE RELAXATION; HEART PROTECTION; MITOCHONDRION; NONHUMAN; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; STREPTOZOCIN DIABETES; ANIMAL; CARDIOMYOPATHY; ENZYMOLOGY; EXPERIMENTAL DIABETES MELLITUS; HEART MITOCHONDRION; HEART MUSCLE; HEART STROKE VOLUME; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SPRAGUE DAWLEY RAT; ULTRASTRUCTURE;

ANIMALS; APOPTOSIS; BRADYKININ; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DIABETES MELLITUS, EXPERIMENTAL; DITERPENES, ABIETANE; GLYCOGEN SYNTHASE KINASE 3; INTERLEUKIN-6; MITOCHONDRIA, HEART; MYOCARDIAL CONTRACTION; MYOCARDIUM; NF-KAPPA B; PEROXIDASE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION; STROKE VOLUME; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 78651333298     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-4     Document Type: Article

References (34)

1. Tschope C, Walther T, Koniger J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M. Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue kallikrein gene. Faseb J 2004, 18(7):828-835. 10.1096/fj.03-0736com, 15117887.
2. Westermann D, Rutschow S, Jager S, Linderer A, Anker S, Riad A, Unger T, Schultheiss HP, Pauschinger M, Tschope C. Contributions of inflammation and cardiac matrix metalloproteinase activity to cardiac failure in diabetic cardiomyopathy: the role of angiotensin type 1 receptor antagonism. Diabetes 2007, 56(3):641-646. 10.2337/db06-1163, 17327431.
3. Zhang L, Cannell MB, Phillips AR, Cooper GJ, Ward ML. Altered calcium homeostasis does not explain the contractile deficit of diabetic cardiomyopathy. Diabetes 2008, 57(8):2158-2166. 10.2337/db08-0140, 2494698, 18492789.
4. Dorenkamp M, Riad A, Stiehl S, Spillmann F, Westermann D, Du J, Pauschinger M, Noutsias M, Adams V, Schultheiss HP, et al. Protection against oxidative stress in diabetic rats: role of angiotensin AT(1) receptor and beta 1-adrenoceptor antagonism. European journal of pharmacology 2005, 520(1-3):179-187. 10.1016/j.ejphar.2005.07.020, 16139267.
5. Li J, Leschka S, Rutschow S, Schwimmbeck PL, Husmann L, Noutsias M, Westermann D, Poller W, Zeichhardt H, Klingel K, et al. Immunomodulation by interleukin-4 suppresses matrix metalloproteinases and improves cardiac function in murine myocarditis. European journal of pharmacology 2007, 554(1):60-68. 10.1016/j.ejphar.2006.08.024, 17113076.
6. Tschope C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, et al. Transgenic activation of the kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. Faseb J 2005, 19(14):2057-2059.
7. Westermann D, Van Linthout S, Dhayat S, Dhayat N, Schmidt A, Noutsias M, Song XY, Spillmann F, Riad A, Schultheiss HP, et al. Tumor necrosis factor-alpha antagonism protects from myocardial inflammation and fibrosis in experimental diabetic cardiomyopathy. Basic research in cardiology 2007, 102(6):500-507. 10.1007/s00395-007-0673-0, 17909696.
8. Nolly HL, Saed G, Scicli G, Carretero OA, Scicli AG. The kallikrein-kinin system in cardiac tissue. Agents and actions 1992, 38(Pt 3):62-72.
9. Gao J, Yang G, Pi R, Li R, Wang P, Zhang H, Le K, Chen S, Liu P. Tanshinone IIA protects neonatal rat cardiomyocytes from adriamycin-induced apoptosis. Transl Res 2008, 151(2):79-87. 10.1016/j.trsl.2007.11.005, 18201675.
10. Sun DD, Wang HC, Wang XB, Luo Y, Jin ZX, Li ZC, Li GR, Dong MQ. Tanshinone IIA: a new activator of human cardiac KCNQ1/KCNE1 (I(Ks)) potassium channels. European journal of pharmacology 2008, 590(1-3):317-321. 10.1016/j.ejphar.2008.06.005, 18573250.
11. Zhou L, Zuo Z, Chow MS. Danshen: an overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. Journal of clinical pharmacology 2005, 45(12):1345-1359. 10.1177/0091270005282630, 16291709.
12. Wei L, Yin Z, Yuan Y, Hwang A, Lee A, Sun D, Li F, Di C, Zhang R, Cao F, Wang H. A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats. Microvascular research 2010, 80(1):158-165.
13. Gao HK, Yin Z, Zhou N, Feng XY, Gao F, Wang HC. Glycogen synthase kinase 3 inhibition protects the heart from acute ischemia-reperfusion injury via inhibition of inflammation and apoptosis. Journal of cardiovascular pharmacology 2008, 52(3):286-292. 10.1097/FJC.0b013e318186a84d, 18806610.
14. Yin Z, Gao H, Wang H, Li L, Di C, Luan R, Tao L. Ischaemic post-conditioning protects both adult and aged Sprague-Dawley rat heart from ischaemia-reperfusion injury through the phosphatidylinositol 3-kinase-AKT and glycogen synthase kinase-3beta pathways. Clinical and experimental pharmacology & physiology 2009, 36(8):756-763.
15. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008, 371(9626):1800-1809. 10.1016/S0140-6736(08)60768-0, 2774464, 18502305.
16. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Reviews in endocrine & metabolic disorders 11(1):31-39.
17. Tarquini R, Lazzeri C, Pala L, Rotella CM, Gensini GF. The diabetic cardiomyopathy. Acta diabetologica 2010,
18. Han JY, Fan JY, Horie Y, Miura S, Cui DH, Ishii H, Hibi T, Tsuneki H, Kimura I. Ameliorating effects of compounds derived from Salvia miltiorrhiza root extract on microcirculatory disturbance and target organ injury by ischemia and reperfusion. Pharmacology & therapeutics 2008, 117(2):280-295.
19. Zhang Y, Wei L, Sun D, Cao F, Gao H, Zhao L, Du J, Li Y, Wang H. Tanshinone IIA pretreatment protects myocardium against ischaemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway in diabetic rats. Diabetes, obesity & metabolism 12(4):316-322.
20. Jiang B, Zhang L, Wang Y, Li M, Wu W, Guan S, Liu X, Yang M, Wang J, Guo DA. Tanshinone IIA sodium sulfonate protects against cardiotoxicity induced by doxorubicin in vitro and in vivo. Food Chem Toxicol 2009, 47(7):1538-1544. 10.1016/j.fct.2009.03.038, 19358873.
21. Hong HJ, Liu JC, Chen PY, Chen JJ, Chan P, Cheng TH. Tanshinone IIA prevents doxorubicin-induced cardiomyocyte apoptosis through Akt-dependent pathway. International journal of cardiology 2010,
22. Mosaddik MA. In vitro cytotoxicity of tanshinones isolated from Salvia miltiorrhiza Bunge against P388 lymphocytic leukemia cells. Phytomedicine 2003, 10(8):682-685. 10.1078/0944-7113-00321, 14692730.
23. Yuan SL, Wei YQ, Wang XJ, Xiao F, Li SF, Zhang J. Growth inhibition and apoptosis induction of tanshinone II-A on human hepatocellular carcinoma cells. World J Gastroenterol 2004, 10(14):2024-2028.
24. Kumar D, Kirshenbaum L, Li T, Danelisen I, Singal P. Apoptosis in isolated adult cardiomyocytes exposed to adriamycin. Annals of the New York Academy of Sciences 1999, 874:156-168. 10.1111/j.1749-6632.1999.tb09233.x, 10415529.
25. Kumar D, Kirshenbaum LA, Li T, Danelisen I, Singal PK. Apoptosis in adriamycin cardiomyopathy and its modulation by probucol. Antioxidants & redox signaling 2001, 3(1):135-145.
26. Fu J, Huang H, Liu J, Pi R, Chen J, Liu P. Tanshinone IIA protects cardiac myocytes against oxidative stress-triggered damage and apoptosis. European journal of pharmacology 2007, 568(1-3):213-221. 10.1016/j.ejphar.2007.04.031, 17537428.
27. Song JQ, Teng X, Cai Y, Tang CS, Qi YF. Activation of Akt/GSK-3beta signaling pathway is involved in intermedin(1-53) protection against myocardial apoptosis induced by ischemia/reperfusion. Apoptosis 2009, 14(11):1299-307. 10.1007/s10495-009-0398-7, 19757065.
28. Dobrin JS, Lebeche D. Diabetic cardiomyopathy: signaling defects and therapeutic approaches. Expert review of cardiovascular therapy 2010, 8(3):373-391. 10.1586/erc.10.17, 20222816.
29. Chao J, Bledsoe G, Yin H, Chao L. The tissue kallikrein-kinin system protects against cardiovascular and renal diseases and ischemic stroke independently of blood pressure reduction. Biological chemistry 2006, 387(6):665-675. 10.1515/BC.2006.085, 16800727.
30. Leeb-Lundberg LM, Marceau F, Muller-Esterl W, Pettibone DJ, Zuraw BL. International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences. Pharmacological reviews 2005, 57(1):27-77. 10.1124/pr.57.1.2, 15734727.
31. Savvatis K, Westermann D, Schultheiss HP, Tschope C. Kinins in cardiac inflammation and regeneration: insights from ischemic and diabetic cardiomyopathy. Neuropeptides 2010, 44(2):119-125. 10.1016/j.npep.2009.11.007, 20036002.
32. Cruden NL, Newby DE. Therapeutic potential of icatibant (HOE-140, JE-049). Expert opinion on pharmacotherapy 2008, 9(13):2383-2390. 10.1517/14656566.9.13.2383, 18710362.
33. Reinking BE, Wedemeyer EW, Weiss RM, Segar JL, Scholz TD. Cardiomyopathy in offspring of diabetic rats is associated with activation of the MAPK and apoptotic pathways. Cardiovascular diabetology 2009, 8:43. 10.1186/1475-2840-8-43, 2731081, 19646268.
34. van den Brom CE, Bosmans JW, Vlasblom R, Handoko LM, Huisman MC, Lubberink M, Molthoff CF, Lammertsma AA, Ouwens MD, Diamant M, et al. Diabetic cardiomyopathy in Zucker diabetic fatty rats: the forgotten right ventricle. Cardiovascular diabetology 2010, 9:25. 10.1186/1475-2840-9-25, 2898761, 20550678.